BIFIDO Co., Ltd. is global immune modulation company based on microbiome. Among various intestinal microbiome, Bifidobacterium is considered to be the most beneficial bacteria to maintain healthy intestinal microbial balance. BIFIDO has focused on research and development of Bifidobacterium spp. since 1999. Over 250 of concerning scientific papers and 80 patents prove that BIFIDO is the top-tier company with the greatest experience and expertise in microbiome industry.Recently, BIFIDO started microbiome research on rheumatoid arthritis (RA), a chronic inflammatory disease. We analyzed the microbiota of RA patients and tried to find a way to treat even those who were less responsive to treatment. We have selected novel Bifidobacterium strains which can improve the symptoms of RA animal model and we expect a new pharmabiotics from those strains. We are now expanding our pipelines for other immune related diseases including cancer.BIFIDO Express Platform is from the selection of pharmabiotics candidates to the production of finished products with various formulations, we have our own R&D and industrialization platform and we are expecting to create mutual profit by BIFIDO Express Platform based collaboration.